Latest Apricus Biosciences Inc (APRI) Headlines
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
Apricus Shares Marginally Down on Vitaros Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 2:44PM CST
Apricus signs deal with Recordati for the commercialization of Vitaros in some countries in Europe and Africa
RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES
GlobeNewswire - Mon Feb 10, 6:06AM CST
Recordati announces the signature of an exclusive license agreement with Apricus Biosciences Inc., (Nasdaq: APRI), a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros(R) (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.
Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream - Vitaros(R) in Spain, Russia, Turkey and Other Global Territories
Thomson Reuters ONE - Mon Feb 10, 6:02AM CST
Apricus Eligible to Receive Up to Approximately $50 Million in Upfront and Milestone Payments, Plus Double-Digit Tiered Royalties
Raynauds Disease - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x6c6p9/raynauds_disease) has announced the addition of the "Raynauds Disease - Pipeline Review, H2 2013" report to their offering. 'Raynauds Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Raynauds Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Raynauds Disease. Scope - A snapshot of the global therapeutic scenario for Raynauds Disease. - A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Raynauds Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Raynauds Disease Overview Therapeutics Development Pipeline Products for Raynauds Disease - Overview Pipeline Products for Raynauds Disease - Comparative Analysis Raynauds Disease - Therapeutics under Development by Companies Raynauds Disease - Therapeutics under Investigation by Universities/Institutes Raynauds Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Raynauds Disease - Products under Development by Companies Raynauds Disease - Products under Investigation by Universities/Institutes Raynauds Disease - Companies Involved in Therapeutics Development Raynauds Disease - Therapeutics Assessment Drug Profiles nitroglycerin - Drug Profile fasudil - Drug Profile udenafil - Drug Profile riociguat - Drug Profile alprostadil - Drug Profile MDT-012 - Drug Profile ELS-140 - Drug Profile Yohimbine Dimers - Drug Profile Yohimbine Monomers - Drug Profile Raynauds Disease - Recent Pipeline Updates Raynauds Disease - Dormant Projects Raynauds Disease - Discontinued Products Raynauds Disease - Product Development Milestones Featured News & Press Releases Companies Mentioned Bayer AG Apricus Biosciences, Inc. MediQuest Therapeutics, Inc. MicroDose Therapeutx, Inc. Exodos Life Science Limited Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/x6...ds_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Apricus Biosciences to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 6:00AM CST
Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com), today announced that Richard Pascoe, Chief Executive Officer, will present at the 16 Annual BIO CEO & Investor Conference, being held at The Waldorf Astoria in New York City. Mr. Pascoe's presentation will take place on Tuesday, February 11, 2014 at 9:30 a.m. Eastern Time.
Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in Belgium
Thomson Reuters ONE - Thu Jan 23, 9:34AM CST
Vitaros(R) Remains on Track for Launch in 2014
Ogun APC - the Trouble That Was Foretold
by Daud Olatunji - All Africa Global Media - Wed Jan 22, 2:09AM CST
The emergence of Senator Ibikunle Amosun as the gubernatorial flag bearer of the defunct Action Congress of Nigeria, ACN in 2011 predicted trouble for the status quo. It didn't take long for it to burst.
KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
PR Newswire - Mon Jan 13, 8:39AM CST
KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel, Stine Seed Company, to the company's Board of Directors. The additions of Mr. Pascoe and Mr. Saluri bring extensive public company and business development experience to KemPharm as the company prepares for multiple clinical and business milestones in 2014, including the expected submission of a New Drug Application (NDA) for KP201, KemPharm's lead clinical candidate, in the third quarter of 2014.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Erectile Dysfunction Drugs Market Report 2013 - 2019
M2 - Thu Jan 02, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28v9tm/erectile) has announced the addition of the "Global Erectile Dysfunction Drugs Market Report 2013 - 2019" report to their offering The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market. Pfizer's Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG. Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million) 5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis 6 Global Erectile Dysfunction Drugs Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Apricus Biosciences - Bayer - Cristalia Produtos Quimicos Farmaceuticos - Dong-A Pharmaceutical - Eli Lilly And Company - Meda Pharmaceuticals - Pfizer - SK Chemicals - Vivus For more information visit http://www.researchandmarkets.com/research/28v9tm/erectile
Apricus Biosciences (APRI) Soars: Stock Up 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 7:39AM CST
Apricus Biosciences, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Can The Uptrend Continue for Apricus Biosciences Inc. (APRI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 6:30AM CST
Can The Uptrend Continue for Apricus Biosciences Inc. (APRI)?
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
Apricus Shares Marginally Down on Vitaros Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 2:44PM CST
Apricus signs deal with Recordati for the commercialization of Vitaros in some countries in Europe and Africa
RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES
GlobeNewswire - Mon Feb 10, 6:06AM CST
Recordati announces the signature of an exclusive license agreement with Apricus Biosciences Inc., (Nasdaq: APRI), a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros(R) (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.
Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream - Vitaros(R) in Spain, Russia, Turkey and Other Global Territories
Thomson Reuters ONE - Mon Feb 10, 6:02AM CST
Apricus Eligible to Receive Up to Approximately $50 Million in Upfront and Milestone Payments, Plus Double-Digit Tiered Royalties
Raynauds Disease - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x6c6p9/raynauds_disease) has announced the addition of the "Raynauds Disease - Pipeline Review, H2 2013" report to their offering. 'Raynauds Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Raynauds Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Raynauds Disease. Scope - A snapshot of the global therapeutic scenario for Raynauds Disease. - A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Raynauds Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Raynauds Disease Overview Therapeutics Development Pipeline Products for Raynauds Disease - Overview Pipeline Products for Raynauds Disease - Comparative Analysis Raynauds Disease - Therapeutics under Development by Companies Raynauds Disease - Therapeutics under Investigation by Universities/Institutes Raynauds Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Raynauds Disease - Products under Development by Companies Raynauds Disease - Products under Investigation by Universities/Institutes Raynauds Disease - Companies Involved in Therapeutics Development Raynauds Disease - Therapeutics Assessment Drug Profiles nitroglycerin - Drug Profile fasudil - Drug Profile udenafil - Drug Profile riociguat - Drug Profile alprostadil - Drug Profile MDT-012 - Drug Profile ELS-140 - Drug Profile Yohimbine Dimers - Drug Profile Yohimbine Monomers - Drug Profile Raynauds Disease - Recent Pipeline Updates Raynauds Disease - Dormant Projects Raynauds Disease - Discontinued Products Raynauds Disease - Product Development Milestones Featured News & Press Releases Companies Mentioned Bayer AG Apricus Biosciences, Inc. MediQuest Therapeutics, Inc. MicroDose Therapeutx, Inc. Exodos Life Science Limited Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/x6...ds_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Apricus Biosciences to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 6:00AM CST
Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com), today announced that Richard Pascoe, Chief Executive Officer, will present at the 16 Annual BIO CEO & Investor Conference, being held at The Waldorf Astoria in New York City. Mr. Pascoe's presentation will take place on Tuesday, February 11, 2014 at 9:30 a.m. Eastern Time.
Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in Belgium
Thomson Reuters ONE - Thu Jan 23, 9:34AM CST
Vitaros(R) Remains on Track for Launch in 2014
Ogun APC - the Trouble That Was Foretold
by Daud Olatunji - All Africa Global Media - Wed Jan 22, 2:09AM CST
The emergence of Senator Ibikunle Amosun as the gubernatorial flag bearer of the defunct Action Congress of Nigeria, ACN in 2011 predicted trouble for the status quo. It didn't take long for it to burst.
KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
PR Newswire - Mon Jan 13, 8:39AM CST
KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel, Stine Seed Company, to the company's Board of Directors. The additions of Mr. Pascoe and Mr. Saluri bring extensive public company and business development experience to KemPharm as the company prepares for multiple clinical and business milestones in 2014, including the expected submission of a New Drug Application (NDA) for KP201, KemPharm's lead clinical candidate, in the third quarter of 2014.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Erectile Dysfunction Drugs Market Report 2013 - 2019
M2 - Thu Jan 02, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28v9tm/erectile) has announced the addition of the "Global Erectile Dysfunction Drugs Market Report 2013 - 2019" report to their offering The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market. Pfizer's Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG. Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million) 5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis 6 Global Erectile Dysfunction Drugs Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Apricus Biosciences - Bayer - Cristalia Produtos Quimicos Farmaceuticos - Dong-A Pharmaceutical - Eli Lilly And Company - Meda Pharmaceuticals - Pfizer - SK Chemicals - Vivus For more information visit http://www.researchandmarkets.com/research/28v9tm/erectile
Apricus Biosciences (APRI) Soars: Stock Up 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 7:39AM CST
Apricus Biosciences, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Can The Uptrend Continue for Apricus Biosciences Inc. (APRI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 6:30AM CST
Can The Uptrend Continue for Apricus Biosciences Inc. (APRI)?
